Literature DB >> 16199342

Severe hypertension in the emergency department patient.

Rachel M Gilmore1, Stephan J Miller, Latha G Stead.   

Abstract

Severely elevated blood pressure is a common clinical problem en-countered in the Emergency Department. It is often difficult for physicians to differentiate between patients who need emergent blood pressure reduction, requiring the use of intravenous agents and in-tensive monitoring, and those for whom careful, slow reduction in BP is more appropriate. The optimal assessment and management of these patients is reviewed here, with an emphasis on clinical strategies that will most efficiently identify those at greatest risk.

Entities:  

Mesh:

Year:  2005        PMID: 16199342     DOI: 10.1016/j.emc.2005.07.012

Source DB:  PubMed          Journal:  Emerg Med Clin North Am        ISSN: 0733-8627            Impact factor:   2.264


  5 in total

1.  Treatment of hypertension in acute ischemic stroke.

Authors:  Anunaya R Jain; M Fernanda Bellolio; Latha G Stead
Journal:  Curr Treat Options Neurol       Date:  2009-03       Impact factor: 3.598

2.  Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.

Authors:  W Frank Peacock; Joseph Varon; Ramin Ebrahimi; Lala Dunbar; Charles V Pollack
Journal:  Blood Press Suppl       Date:  2010-11-23

3.  The impact of blood pressure hemodynamics in acute ischemic stroke: a prospective cohort study.

Authors:  Latha Ganti Stead; Sailaja Enduri; M Fernanda Bellolio; Anunaya R Jain; Lekshmi Vaidyanathan; Rachel M Gilmore; Rahul Kashyap; Amy L Weaver; Robert D Brown
Journal:  Int J Emerg Med       Date:  2012-01-17

4.  An atypical case of two instances of mepivacaine toxicity.

Authors:  Alberto Manassero; Matteo Bossolasco; Susanna Ugues; Cristian Bailo
Journal:  J Anaesthesiol Clin Pharmacol       Date:  2014-10

5.  Parenteral clevidipine for the acute control of blood pressure in the critically ill patient: a review.

Authors:  W Frank Peacock; Jorge E Angeles; Karina M Soto; Philip D Lumb; Joseph Varon
Journal:  Ther Clin Risk Manag       Date:  2009-08-03       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.